ECSP11011032A - Pirrolidinas - Google Patents
PirrolidinasInfo
- Publication number
- ECSP11011032A ECSP11011032A EC2011011032A ECSP11011032A ECSP11011032A EC SP11011032 A ECSP11011032 A EC SP11011032A EC 2011011032 A EC2011011032 A EC 2011011032A EC SP11011032 A ECSP11011032 A EC SP11011032A EC SP11011032 A ECSP11011032 A EC SP11011032A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- formula
- preparation
- pelvic pain
- chronic pelvic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una clase de compuestos de pirrolidina de fórmula (I), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. También se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (I) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del riñón poliquístico y el síndrome del ovario poliquístico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011032A true ECSP11011032A (es) | 2011-06-30 |
Family
ID=41503565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011032A ECSP11011032A (es) | 2008-11-10 | 2011-05-05 | Pirrolidinas |
Country Status (31)
Country | Link |
---|---|
US (1) | US8278343B2 (es) |
EP (1) | EP2364296A1 (es) |
JP (1) | JP2012508225A (es) |
KR (1) | KR20110083733A (es) |
CN (1) | CN102209710A (es) |
AP (1) | AP2011005728A0 (es) |
AR (1) | AR074314A1 (es) |
AU (1) | AU2009312427B2 (es) |
BR (1) | BRPI0920924A2 (es) |
CA (1) | CA2741589A1 (es) |
CL (1) | CL2011001034A1 (es) |
CO (1) | CO6382112A2 (es) |
CR (1) | CR20110217A (es) |
CU (1) | CU20110093A7 (es) |
DO (1) | DOP2011000127A (es) |
EA (1) | EA201100549A1 (es) |
EC (1) | ECSP11011032A (es) |
GE (1) | GEP20125607B (es) |
IL (1) | IL212490A0 (es) |
MA (1) | MA32782B1 (es) |
MX (1) | MX2011004903A (es) |
NI (1) | NI201100092A (es) |
NZ (1) | NZ592311A (es) |
PA (1) | PA8848001A1 (es) |
PE (1) | PE20110663A1 (es) |
SV (1) | SV2011003896A (es) |
TN (1) | TN2011000211A1 (es) |
TW (1) | TW201022234A (es) |
UY (1) | UY32228A (es) |
WO (1) | WO2010052625A1 (es) |
ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
WO2013176220A1 (ja) * | 2012-05-25 | 2013-11-28 | 国立大学法人京都大学 | 概日リズム調整 |
CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
WO2022272062A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5319099A (en) * | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
JP4554931B2 (ja) * | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | プロスタグランジン調節物質としてのピロリジン誘導体 |
WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
WO2008139287A1 (en) * | 2007-05-10 | 2008-11-20 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
-
2009
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko active IP Right Grant
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en active Application Filing
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8278343B2 (en) | 2012-10-02 |
CL2011001034A1 (es) | 2011-11-11 |
CO6382112A2 (es) | 2012-02-15 |
JP2012508225A (ja) | 2012-04-05 |
GEP20125607B (en) | 2012-08-10 |
CR20110217A (es) | 2011-05-12 |
WO2010052625A1 (en) | 2010-05-14 |
AU2009312427B2 (en) | 2011-10-20 |
AP2011005728A0 (en) | 2011-06-30 |
EA201100549A1 (ru) | 2011-12-30 |
US20100120793A1 (en) | 2010-05-13 |
SV2011003896A (es) | 2011-07-05 |
AU2009312427A1 (en) | 2010-05-14 |
AR074314A1 (es) | 2011-01-05 |
EP2364296A1 (en) | 2011-09-14 |
TN2011000211A1 (fr) | 2012-12-17 |
CA2741589A1 (en) | 2010-05-14 |
IL212490A0 (en) | 2011-06-30 |
TW201022234A (en) | 2010-06-16 |
NI201100092A (es) | 2011-10-31 |
UY32228A (es) | 2010-06-30 |
MX2011004903A (es) | 2011-05-30 |
PE20110663A1 (es) | 2011-09-23 |
PA8848001A1 (es) | 2010-06-28 |
MA32782B1 (fr) | 2011-11-01 |
DOP2011000127A (es) | 2011-07-15 |
BRPI0920924A2 (pt) | 2016-10-04 |
CN102209710A (zh) | 2011-10-05 |
NZ592311A (en) | 2012-12-21 |
ZA201104310B (en) | 2012-02-29 |
CU20110093A7 (es) | 2012-01-31 |
KR20110083733A (ko) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8827901A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
DOP2021000183A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
ECSP11011032A (es) | Pirrolidinas | |
CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
CR11061A (es) | Derivados de piridina | |
CO6400220A2 (es) | Derivados de sulfonamida | |
CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
UY32574A (es) | Antagonistas del receptor cxcr3 | |
CY1114260T1 (el) | 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγο, μεθοδοι για την παραγωγη αυτου και χρηση αυτου για την αγωγη παθησεων | |
CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
PA8623101A1 (es) | Compuestos farmaceuticamente activos | |
CR11101A (es) | Azetidinas | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
EA200970849A1 (ru) | Трициклические производные изохинолина для лечения ожирения | |
AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
CR9595A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
CL2021000184A1 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
CO6690116A1 (es) | Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen | |
ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
CL2017002969A1 (es) | Derivados de etinilo | |
CO6331339A2 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
CU20100217A7 (es) | Derivados de quinuclidina como antagonistas de receptores muscarínicos m3 | |
DOP2010000347A (es) | Derivados de quinuclidina como antagonistas de recpetores muscarinicos m3 |